China Blood Product Industry, 2011-2016 is a new market research publication announced by Reportstack. Blood products made by segregating and purifying all kinds of proteins in the blood plasma consists of albumin, immunoglobulin, thrombinogen and other products. China's enterprises mainly produce 9 kinds of products in the first three categories.
The high concentration rate of the global blood product market is embodied in the three companies of developed countries accounting for more than 80% of the global market. The current global blood market remains relatively stable, of which the emerging economy is the main motivation of growth. By the end of 2015, there were 33 blood product manufacturing enterprises certified by the government in China, but in fact, only 20 of them were in production. Since 2012, mergers and acquisitions are common in China's blood product industry. For example, Jiangxi Boya Bio-Pharmaceutical Co., Ltd. acquired partial stock rights of Zhejiang Haikang Biologicals Co., Ltd. Beijing Tiantan Biological Products Co., Ltd. purchased Chengdu Rosen Pharmaceutical Co., Ltd. Watson Biological Company acquired Hebei Docan Pharmaceutical Co., Ltd. Shanghai RAAS Blood Products Co., Ltd. purchased Zhengzhou Banghe Pharmaceutical Co., Ltd. China National Biotec Group acquired Guiyang Qianfeng Biological Products Co., Ltd. and Xi'an Huitian Blood Products Co., Ltd. Humanwell Healthcare Group Co., Ltd. purchased Wuhan Rui De Biological Products Co., Ltd.
In 2015, 8,000 tons of blood plasma was needed to meet the demand of Chinese market, and the actual supply was only 5,000 tons. For example, the demand for blood products of about 1.4 billion population of China should be 12,000 tons calculated according to per capita demand of the normal blood products of the World Health Organization, which is far more than the actual supply of China.
To access full report with TOC, please visit China Blood Product Industry, 2011-2016.
In China's blood product industry, the scale of the blood plasma has been the main bottleneck restricting the development of blood product industry. The quality and quantity of plasma stations are of vital importance.
In 2001, Chinese government announced that no new blood product manufacturing enterprises would be approved to ensure the safety of blood and its products, and block the spread of HIV through collection and supply of blood .
In 2008, Chinese government formulated the regulations that the plasma collection regions should guarantee the quantity of the plasma donors, which can satisfy no less than 30 tons' collection of source plasma. In 2011, Guizhou government announced the program of adjusting the settings of blood services. The plasma collection stations decreased from 20 to 4, of which Hualan Biological Engineering Co., Ltd., the blood product giant, suffered the most. The plasma stations of Guizhou Province decreased from 6 to 1, having reduced half of the corporate source plasma supply.
Lack of the local blood products, but Chinese government has issued strict regulations on the import of blood products. Only human serum albumin and three kinds of thrombinogen are allowed to be imported.
In recent years, the competitiveness of China's blood product market has been mainly determined by the amount of blood plasma resources. Under the tense condition of source plasma supply, blood product manufacturing enterprises will obtain more space for survival and development with more blood plasma stations and source plasma.
There are only two channels for overseas blood product enterprise to enter Chinese market. One is to export products to China directly. The other one is to enter Chinese market indirectly through such means as equity acquisition.
Information Included in this report:
-Current Situation of the Global Blood Product Industry
-Development History and Current Situation of China's Blood Products
-Government Policies of China's Blood Product Industry
-Niche Products' Current Situation of China's Blood Product
-Market Competition of China's Blood Product Industry
-China's Major Blood Product Enterprises and Their Operation Status
-Development Trend of China's Blood Product Industry
Who can Purchase This Report:
-Blood Product Manufacturing Enterprises
-Blood Product Regulatory Agency
-Investors /Research Agencies Focusing on Blood Product Industry
Shanghai RAAS Blood Products Co. Ltd. Hualan Biological Engineering Co., Ltd. Beijing Tiantan Biological Products Co., Ltd. (Subsidiary of China National Biotec Group Company Limited) Guangdong Shuanglin Bio-pharmaceutical Co., Ltd. Jiangxi Boya Bio-pharmaceutical Co., Ltd. Hunan Nanyue Pharmaceutical Co., Ltd. Wuhan Rui De Biological Products Co., Ltd. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Green Cross Biological Products Co., Ltd. Guiyang Qianfeng Biological Products Co., Ltd. Anhui Da'an Biological Products Co., Ltd. Shenzhen Weiguang Biological Products Co., Ltd. Shandong Taibang Products Co., Ltd. Subordinate Institutions of Biological Products of China National Biotec Group
Manager - Marketing
Reportstack Market Research